Literature DB >> 7977094

A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction.

C B Granger1, H D White, E R Bates, E M Ohman, R M Califf.   

Abstract

Individual studies of patency rates and left ventricular (LV) function after thrombolysis have generally been limited by small numbers of observations, wide confidence intervals, and limited numbers of time points. To obtain a more reliable estimate of patterns of patency and LV ejection fraction, a systemic overview of angiographic studies was performed after intravenous thrombolytic therapy. A total of 14,124 angiographic observations from 58 studies evaluating patency after no thrombolytic agent, streptokinase, standard dose tissue-type plasminogen activator (t-PA), accelerated dose t-PA, or anistreplase (anisoylated plasminogen streptokinase activator complex [APSAC]) were included. At 60 and 90 minutes, streptokinase had the lowest patency rates of 48% and 51%, respectively, standard dose t-PA and APSAC had similar intermediate rates of approximately 60% and 70%, and accelerated t-PA had the highest patency rates of 74% and 84%. By 2 to 3 hours and longer, the patency rates were similar for the various regimens. Reocclusion rates in studies including 1,172 patients randomized to t-PA versus a nonfibrin-specific agent were higher after t-PA (13.4% vs 8.0%, p = 0.002). Ten studies enrolling 4,088 patients treated with thrombolytic therapy versus control demonstrated a modest improvement in mean LV ejection fraction in the thrombolytic group at each of the times after thrombolytic therapy: hour 4, day 1, day 4, day 7 to 10, and day 10 to 28 after thrombolysis. By 4 days, mean ejection fraction was 53% versus 47% (thrombolytic vs control therapy, p < 0.01); by 10 to 28 days it was 54.1% and 51.5%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7977094     DOI: 10.1016/0002-9149(94)90552-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  Emergency management of acute myocardial infarction.

Authors:  S Maxwell
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Primary angioplasty should be first line treatment for acute myocardial infarction: AGAINST.

Authors:  Kevin S Channer
Journal:  BMJ       Date:  2004-05-22

3.  [Prediction of outcome in ST elevation myocardial infarction by the extent of ST segment deviation recovery. Which method is best?].

Authors:  K Schröder; U Zeymer; W Wegschneider; R Schröder
Journal:  Z Kardiol       Date:  2004-08

4.  The Open-Artery Hypothesis: An Overview.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 5.  Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction.

Authors:  Michael A Morse; Josh W Todd; George A Stouffer
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

6.  ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

Authors:  C Baigent; R Collins; P Appleby; S Parish; P Sleight; R Peto
Journal:  BMJ       Date:  1998-05-02

7.  Where will the next generation of stroke treatments come from?

Authors:  D W Howells; G A Donnan
Journal:  PLoS Med       Date:  2010-03-02       Impact factor: 11.069

Review 8.  Glycoprotein IIb/IIIa receptor inhibitor-thrombolytic combination therapy for acute myocardial infarction.

Authors:  Ara M Maranian; Steven R Steinhubl
Journal:  Curr Cardiol Rep       Date:  2002-07       Impact factor: 2.931

9.  Global Thrombosis Test: Occlusion Is Attributable to Shear-Induced Platelet Thrombus Formation.

Authors:  Diana A Gorog; Junichiro Yamamoto
Journal:  TH Open       Date:  2021-12-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.